Literature DB >> 2139843

Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone.

N van der Vange1, M A Blankenstein, H J Kloosterboer, A A Haspels, J H Thijssen.   

Abstract

The effect of seven low-dose oral contraceptive preparations on sex hormone binding globulin (SHBG), cortisol binding globulin (CBG), total and absolute free testosterone were investigated in groups of 10 healthy volunteers. All preparations contained about the same amount of ethinylestradiol but they differed in type and/or dose of progestagen. The progestagens studied were: levonorgestrel (LNG; in mono- and triphasic preparations), norethisterone (NET; in monophasic preparation), desogestrel (DSG; in mono- and biphasic preparations) and gestodene (GSD; in triphasic preparation), all 19-nortestosterone derivatives, and the anti-androgen cyproterone acetate (CPA) in a monophasic preparation. Differences observed in SHBG level, which reflect the estrogen-androgen balance, can be attributed to the intrinsic androgenic (or anti-androgenic) properties of the progestagens, and were in agreement with the results of published receptor binding studies, performed in vitro. Based on our results the following ranking (high to low) can be made with respect to the androgenicity of the preparations: monophasic LNG greater than or equal to monophasic NET = triphasic LNG greater than or equal to triphasic GSD = biphasic DSG = monophasic DSG greater than monophasic CPA. An anti-estrogenic effect of the 19-nortestosterone derived progestagens can be excluded by the effect on CBG, a marker for estrogenic activity. All preparations containing a 19-nortestosterone derived progestagen, independent of their type and dose, induce a similar rise in CBG, whereas the preparation with cyproterone acetate induced an even higher CBG level. Irrespective of the effect on total testosterone, which varies between the preparations, the absolute free testosterone level decreased to a comparable degree for all preparations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139843     DOI: 10.1016/0010-7824(90)90034-s

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  24 in total

1.  Oral contraceptives and sexuality in university women.

Authors:  N L McCoy; J R Matyas
Journal:  Arch Sex Behav       Date:  1996-02

Review 2.  Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations.

Authors:  M I Wilde; J A Balfour
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

3.  Effects of Estrogen Replacement on Bone Geometry and Microarchitecture in Adolescent and Young Adult Oligoamenorrheic Athletes: A Randomized Trial.

Authors:  Kathryn E Ackerman; Vibha Singhal; Meghan Slattery; Kamryn T Eddy; Mary L Bouxsein; Hang Lee; Anne Klibanski; Madhusmita Misra
Journal:  J Bone Miner Res       Date:  2019-11-07       Impact factor: 6.741

Review 4.  Comparative pharmacology of newer progestogens.

Authors:  H Kuhl
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

5.  Circulating cortisol levels after exogenous cortisol administration are higher in women using hormonal contraceptives: data from two preliminary studies.

Authors:  Allison E Gaffey; Michelle M Wirth; Roxanne M Hoks; Allison L Jahn; Heather C Abercrombie
Journal:  Stress       Date:  2014-07       Impact factor: 3.493

6.  Rheumatoid arthritis, the contraceptive pill, and androgens.

Authors:  W H James
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

7.  Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis.

Authors:  Jeffrey T Jensen; Anne E Burke; Kurt T Barnhart; Carrie Tillotson; Marci Messerle-Forbes; Dawn Peters
Journal:  Contraception       Date:  2008-08-28       Impact factor: 3.375

Review 8.  Evidence for a Non-Genomic Action of Testosterone in Skeletal Muscle Which may Improve Athletic Performance: Implications for the Female Athlete.

Authors:  Jessica R Dent; Deborah K Fletcher; Michael R McGuigan
Journal:  J Sports Sci Med       Date:  2012-09-01       Impact factor: 2.988

9.  Clotting factor changes during the first cycle of oral contraceptive use.

Authors:  Carolyn L Westhoff; Andrew Eisenberger; Rosalind Tang; Serge Cremers; Lisa V Grossman; Malcolm C Pike
Journal:  Contraception       Date:  2015-10-09       Impact factor: 3.375

10.  Using changes in binding globulins to assess oral contraceptive compliance.

Authors:  Carolyn L Westhoff; Kelsey A Petrie; Serge Cremers
Journal:  Contraception       Date:  2012-07-12       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.